NewsEpisurf Medical Interim Report 1 January – 31 March, 2017

First quarter compared to 2016, Group
» Group net sales increased by 12% to SEK 462,979 (411,834).
» Other operating income amounted to SEK 71,902 (565,286).
» Income after financial items amounted to SEK –19,036,869 (–11,696,747).
» Earnings per share (weighted average) amounted to SEK –0.66 (–0.89).

Significant events during the first quarter
» Episurf Medical announced and conducted a rights issue and raised approximately SEK 109.5 M prior to transaction costs.
» Episurf Medical is expanded its Clinical Advisory Board.
» Dennis D. Stripe to act as executive chairman.
» Episurf Medical obtained its first granted patents in China.
» Positive patent development in the US for Episurf Medical’s 3D-based damage assessment tool.
» Episurf Medicals CEO Rosemary Cunningham Thomas stepped down – search for new CEO initiated.

Significant events after the first quarter
» Episurf Medical announced that the 50th implantation in Germany of the Episealer® knee implant will take place in the coming days.
» Episurf Medical obtained further granted patent in Australia.
» Episurf Medical strengthened the company’s management group.
» Episurf Medical obtained further granted patent in the US.
» Episurf Medical reached milestone of 200 Implants

For more information, please contact:
Pål Ryfors, acting CEO, Episurf Medical
Tel: +46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com